Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$121 Mln
Revenue (TTM)
$5 Mln
Net Profit (TTM)
$-18 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
--
EV/EBITDA
0.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
21,997,000
CFO
$-145.87 Mln
EBITDA
$-160.58 Mln
Net Profit
$-160.12 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Graybug Vision (GRAY)
| 546.0 | -19.3 | -62.8 | 288.2 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Graybug Vision (GRAY)
| -72.7 | -93.7 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Graybug Vision (GRAY)
|
3.2 | 121.0 | 5.4 | -38.0 | -895.4 | -119.4 | -- | 0.3 |
| 0.1 | 2.0 | 0.7 | -7.7 | -- | -112.5 | -- | 0.7 |
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a... microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California. Read more
Pres, CEO, Sec. & Director
Dr. Frederic Guerard Pharm.D.
Pres, CEO, Sec. & Director
Dr. Frederic Guerard Pharm.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Graybug Vision Inc (GRAY) is $3.23 (NASDAQ) as of 23-May-2023 09:30 EDT. Graybug Vision Inc (GRAY) has given a return of 288.22% in the last 1 years.
Since, TTM earnings of Graybug Vision Inc (GRAY) is negative, P/E ratio is not available.
The P/B ratio of Graybug Vision Inc (GRAY) is 0.30 times as on 23-May-2023, a 93 discount to its peers’ median range of 4.12 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Graybug Vision Inc (GRAY) are Rs -- and Rs -- as of 04-Apr-2026.
Graybug Vision Inc (GRAY) has a market capitalisation of $ 121 Mln as on 23-May-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Graybug Vision Inc (GRAY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.28
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.